Cover Image
Market Research Report
Product code 
942920

European Breast Cancer Diagnostics And Therapeutics Market 2019-2025

Published: | Orion Market Research Pvt Ltd | Delivery time: 2-3 business days

Price

Back to Top
European Breast Cancer Diagnostics And Therapeutics Market 2019-2025
Published: February 21, 2020
Orion Market Research Pvt Ltd
Delivery time: 2-3 business days
  • ALL
  • Description
  • Table of Contents
Description

European Breast Cancer Diagnostics And Therapeutics Market Size, Share & Trends Analysis Report by Cancer Type (DCIS, IDC, TNBC), Inflammatory Breast Cancer and Others), By Diagnostics (Mammography, Biopsy, PET/CET, Ultrasound, and Others), By Therapeutics(Laboratory testing and Point of care testing) and Forecast 2019-2025

European breast cancer diagnostics and therapeutics market are estimated to grow significantly at a CAGR of 9.2% during the forecast period. The market is mainly driven due to the high prevalence of breast cancer within European countries that include UK, Germany, Italy Spain, and others. These countries play a significant role in growth including awareness programs, the introduction of new imaging technologies and government expenditure on breast cancer diagnosis and treatment. The European Breast Cancer Coalition works to raise awareness of breast cancer. The European Commission launched the European Commission Initiative on Breast Cancer (ECIBC) in 2012 to ensure that all breast cancer care processes are performed with quality and correctly in all citizens in Europe. The objective of ECIBC was to establish a voluntary European quality assurance scheme for breast cancer services including screening, diagnosis, treatment, rehabilitation, survivorship care and palliative care. These initiatives enable the growth and diagnosis rates that influenced the breast cancer market.

European breast cancer diagnosis and therapeutics market are segmented on the basis of cancer type, diagnostics, and therapeutics. In cancer type segment market is further classified into ductal carcinoma in-situ (DCIS), invasive ductal carcinoma (IDC), triple negative breast cancer (TNBC), inflammatory breast cancer and others. In diagnostics technology, the segment market is further classified into mammography, biopsy, position emission tomography/Computed tomography, ultrasound, and others. The therapeutics technology segment market is further segregated into chemotherapy, hormone therapy, targeted therapy, and others.

The companies which are contributing to the growth of the European breast cancer diagnostics and therapeutics market include, Agendia NV, AstraZeneca PLC, Bayer AG, GlaxoSmithKline PLC, Mylan NV, Merck & Co., Inc., Novartis International AG, F. Hoffmann-La Roche AG, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market.

Research Methodology

The market study of the European breast cancer diagnostics and therapeutics market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for biotechnology companies, research institutes, hospitals, and government organizations for the overall market and competitive analysis. The report provides an in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. European breast cancer diagnostics and therapeutics Market Research and Analysis by Cancer Type

2. European breast cancer diagnostics and therapeutics Market Research and Analysis by Diagnostics

3. European breast cancer diagnostics and therapeutics Market Research and Analysis by Therapeutics

The Report Covers:

  • Comprehensive research methodology of the European breast cancer diagnostics and therapeutics market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the European breast cancer diagnostics and therapeutics market.
  • Insights about market determinants which are stimulating the European breast cancer diagnostics and therapeutics market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Table of Contents
Product Code: OMR2020958

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. European Breast Cancer Diagnostics and Therapeutics Market by Cancer Type
    • 5.1.1. Ductal Carcinoma In-Situ (DCIS)
    • 5.1.2. Invasive Ductal Carcinoma (IDC)
    • 5.1.3. Triple Negative Breast Cancer (TNBC)
    • 5.1.4. Inflammatory Breast Cancer
    • 5.1.5. Others (Invasive lobular carcinoma)
  • 5.2. European Breast Cancer Diagnostics and Therapeutics Market by Diagnostics
    • 5.2.1. Mammography
    • 5.2.2. Biopsy
    • 5.2.3. PET/CET
    • 5.2.4. Ultrasound
    • 5.2.5. Others (MRI)
  • 5.3. European Breast Cancer Diagnostics and Therapeutics Market by Therapeutics
    • 5.3.1. Chemotherapy
    • 5.3.2. Hormone Therapy
    • 5.3.3. Targeted Therapy
    • 5.3.4. Others (Radiation Therapy, Surgery)

6. Regional Analysis

  • 6.1. UK
  • 6.2. Germany
  • 6.3. France
  • 6.4. Italy
  • 6.5. Spain
  • 6.6. Rest of Europe

7. Company Profiles

  • 7.1. Agendia NV
  • 7.2. AstraZeneca PLC
  • 7.3. Bayer AG
  • 7.4. GlaxoSmithKline PLC
  • 7.5. Mylan NV
  • 7.6. Merck & Co., Inc.
  • 7.7. Novartis International AG
  • 7.8. F. Hoffmann-La Roche AG
  • 7.9. Sanofi S.A.
  • 7.10. Siemens Healthcare GmbH

List of Tables

  • 1. EUROPEAN BREAST CANCER DIAGNOSTICS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 2. EUROPEAN BREAST CANCER DIAGNOSTICS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2018-2025 ($ MILLION)
  • 3. EUROPEAN BREAST CANCER DIAGNOSTICS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DIAGNOSTICS, 2018-2025 ($ MILLION)
  • 4. EUROPEAN BREAST CANCER DIAGNOSTICS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPEUTICS, 2018-2025 ($ MILLION)

List of Figures

  • 1. EUROPEAN BREAST CANCER DIAGNOSTICS AND THERAPEUTICS MARKET SHARE BY COUNTRY, 2018 VS 2025 (%)
  • 2. EUROPEAN BREAST CANCER DIAGNOSTICS AND THERAPEUTICS MARKET SHARE BY CANCER TYPE, 2018 VS 2025 (%)
  • 3. EUROPEAN BREAST CANCER DIAGNOSTICS AND THERAPEUTICS MARKET SHARE BY DIAGNOSTICS, 2018 VS 2025 (%)
  • 4. EUROPEAN BREAST CANCER DIAGNOSTICS AND THERAPEUTICS MARKET SHARE BY THERAPEUTICS, 2018 VS 2025 (%)
  • 5. UK BREAST CANCER DIAGNOSTICS AND THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 6. GERMANY BREAST CANCER DIAGNOSTICS AND THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 7. FRANCE BREAST CANCER DIAGNOSTICS AND THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 8. ITALY BREAST CANCER DIAGNOSTICS AND THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 9. SPAIN BREAST CANCER DIAGNOSTICS AND THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 10. REST OF EUROPE BREAST CANCER DIAGNOSTICS AND THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)